Leon Scrimmager, MD
Internal Medicine · New York, NYNPI 1215020474
Payments from drug & device makers
Across 123 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$451
- Gilead$369
- GSK$219
- Amarin Pharma, Inc.$214
- AbbVie$204
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- plus $821 from 16 others
What the payments were for
- Food & beverage$2,460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $451 |
| Gilead | 7 | $369 |
| GSK | 17 | $219 |
| Amarin Pharma, Inc. | 11 | $214 |
| AbbVie(2 entities) | 11 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $183 |
| Boston Scientific | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Vertical Pharmaceuticals, LLC | 5 | $91 |
| Novo Nordisk | 5 | $78 |
| Bausch Health US, LLC | 5 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Assertio Therapeutics, Inc. | 3 | $46 |
| Medicomp Inc | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $38 |
| Biogen | 2 | $35 |
| QOL Medical, LLC | 2 | $32 |
| AstraZeneca | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Truvada$244
- RELISTOR$125
- LUCEMYRA$125
- SPECTRA WAVEWRITER$116
How this compares
$2,460 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 17 | $19,660 |
| EliquisApixaban | 14 | $17,104 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 15 | $4,394 |
| Oxycodone Hcl | 95 | $1,791 |
| Gabapentin | 59 | $543 |
| Telmisartan | 15 | $518 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 11 | $452 |
| Atorvastatin Calcium | 38 | $376 |
| Amlodipine Besylate | 59 | $335 |
| Metoprolol Succinate | 19 | $320 |
| Rosuvastatin Calcium | 17 | $301 |
| Omeprazole | 41 | $284 |
| Levothyroxine Sodium | 22 | $199 |
| Lisinopril | 25 | $112 |
| Metformin Hcl | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.